<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0CF6353C-24C9-4866-99CF-FB1DB633AF6F"><gtr:id>0CF6353C-24C9-4866-99CF-FB1DB633AF6F</gtr:id><gtr:name>University of North Carolina at Chapel Hill</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83570C3E-9613-45EB-BCBE-966B13BFAE4B"><gtr:id>83570C3E-9613-45EB-BCBE-966B13BFAE4B</gtr:id><gtr:name>University of Twente</gtr:name><gtr:address><gtr:line1>PO Box 217</gtr:line1><gtr:postCode>7500 AE</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9"><gtr:id>ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9</gtr:id><gtr:name>Curie Institute Paris (Institut Curie)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/047EBC73-8511-4B50-9680-1D19A68EA3E8"><gtr:id>047EBC73-8511-4B50-9680-1D19A68EA3E8</gtr:id><gtr:name>Free University of Amsterdam</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/617E7220-F6C8-489B-991E-AFD367E83A93"><gtr:id>617E7220-F6C8-489B-991E-AFD367E83A93</gtr:id><gtr:name>Aix-Marseille University</gtr:name><gtr:address><gtr:line1>Aix-Marseille University</gtr:line1><gtr:line2>Pharo</gtr:line2><gtr:line4>Marseille</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Obstetrics and Gynaecology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0CF6353C-24C9-4866-99CF-FB1DB633AF6F"><gtr:id>0CF6353C-24C9-4866-99CF-FB1DB633AF6F</gtr:id><gtr:name>University of North Carolina at Chapel Hill</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83570C3E-9613-45EB-BCBE-966B13BFAE4B"><gtr:id>83570C3E-9613-45EB-BCBE-966B13BFAE4B</gtr:id><gtr:name>University of Twente</gtr:name><gtr:address><gtr:line1>PO Box 217</gtr:line1><gtr:postCode>7500 AE</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9"><gtr:id>ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9</gtr:id><gtr:name>Curie Institute Paris (Institut Curie)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/047EBC73-8511-4B50-9680-1D19A68EA3E8"><gtr:id>047EBC73-8511-4B50-9680-1D19A68EA3E8</gtr:id><gtr:name>Free University of Amsterdam</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/617E7220-F6C8-489B-991E-AFD367E83A93"><gtr:id>617E7220-F6C8-489B-991E-AFD367E83A93</gtr:id><gtr:name>Aix-Marseille University</gtr:name><gtr:address><gtr:line1>Aix-Marseille University</gtr:line1><gtr:line2>Pharo</gtr:line2><gtr:line4>Marseille</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BD38DCC7-C263-4294-B336-497F7AB6CE05"><gtr:id>BD38DCC7-C263-4294-B336-497F7AB6CE05</gtr:id><gtr:firstName>Dionne</gtr:firstName><gtr:surname>Tannetta</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/61166E76-0D06-493F-A563-7E5C5465018B"><gtr:id>61166E76-0D06-493F-A563-7E5C5465018B</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>L.</gtr:otherNames><gtr:surname>Sargent</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/857D6D86-9AEC-4CA3-868C-4755BC834842"><gtr:id>857D6D86-9AEC-4CA3-868C-4755BC834842</gtr:id><gtr:firstName>Manu</gtr:firstName><gtr:surname>Vatish</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/53913E61-347B-493B-8919-DA3F6658DF58"><gtr:id>53913E61-347B-493B-8919-DA3F6658DF58</gtr:id><gtr:firstName>Gavin</gtr:firstName><gtr:surname>Collett</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DE16A300-2D0E-47E6-A8E3-8C2C7A0F610D"><gtr:id>DE16A300-2D0E-47E6-A8E3-8C2C7A0F610D</gtr:id><gtr:firstName>Chris</gtr:firstName><gtr:surname>Gardiner</gtr:surname><gtr:orcidId>0000-0002-2318-0062</gtr:orcidId><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EC6F75D8-60C5-4063-A7B4-DD2C06964EAA"><gtr:id>EC6F75D8-60C5-4063-A7B4-DD2C06964EAA</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Willard</gtr:otherNames><gtr:surname>Redman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ003360%2F1"><gtr:id>32C5BF21-B14A-46E3-9F6C-DBD846B01670</gtr:id><gtr:title>Trophoblast Microvesicles, Exosomes, miRNAs, Danger Molecules and Pre-eclampsia</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J003360/1</gtr:grantReference><gtr:abstractText>Pre-eclampsia is a complication of the second half of pregnancy which affects 2.5-3.0% of women. It has the potential to kill mother or baby or both, but cannot yet be prevented. It is the commonest reason for induced preterm delivery, which can lead to fetal handicap and has long term health consequences for both mother and child. No other complication of pregnancy is so common and so dangerous for both mother and baby. The disease originates in the placenta, the supply line for the unborn child, and evolves in two stages. The first stage, without any symptoms at 2-4 months of pregnancy, involves poor development of the blood supply to the placenta, leading to placental damage. The second stage, which occurs in the second half of pregnancy, involves activation of an inflammatory response in the mother's blood stream with damage to the blood vessels, leading to the high blood pressure and protein in the urine, which characterise the disorder. The first and second stages are believed to be linked by the release of inflammatory factors (collectively known as &amp;quot;danger&amp;quot; molecules) from the surface of the damaged placenta into the maternal blood, which interact with maternal inflammatory and endothelial cells to cause the disease. These danger molecules are the focus of this programme. 

We believe that pre-eclampsia is caused not by one, but by many different danger molecules working together. These may be shed from the placenta either as soluble factors or associated with tiny fragments of cells called microvesicles and exosomes. These sub-cellular vesicles are now known to be an important way that cells communicate with each other. We have previously found that there are significantly more placental vesicles in the circulation of pre-eclamptic compared to normal pregnant women and that they can affect the function of immune and endothelial cells in the laboratory. We have found that these vesicles carry over 2,500 different molecules, many of which may be dangerous to the mother. These vesicles may, in effect, be acting like &amp;quot;cluster bombs&amp;quot;, carrying multiple warheads to their target cells to cause the maximum damage. Thus they may play a key role in the disease process. 

The purpose of this programme is to learn more about these vesicles, how they differ between normal and pre-eclamptic pregnancy and their role in the development of pre-eclampsia. As they are released into the mother's blood they provide us with easily accessible tiny biopsies of the placenta which give us a unique window on what is happening in the placenta during the development of the disease. The ultimate aim therefore is to isolate them from the maternal circulation and use them as markers to diagnose or predict pre-eclampsia. Understanding the make up of these vesicles may also help us develop potential treatments in the future. 

Until recently most of these vesicles have been inaccessible because of their small size - below the limits of microscopy and other standard laboratory equipment. In this research we will use unique technology that we have developed that allows us to see the full range of circulating vesicles and distinguish those that come from the placenta from those that come from the mother's own systems. Our preliminary work, demonstrates that these previously 'invisible' particles form the major part of circulating vesicles; hence they are completely new territory for pre-eclampsia research.</gtr:abstractText><gtr:technicalSummary>We will use placental perfusion to examine, (by proteomics and miRNA arrays), which danger molecules and miRNAs, shed from the placenta's syncytiotrophoblast surface, are soluble, and which are part of syncytiotrophoblast vesicles (STBM). As STBM comprise both smaller exosomes (STBex) and larger microvesicles (STBmic), with different possible biological functions, we will fractionate them (e.g. by nanofiltration) to determine their phenotypes and the differences between normal pregnancy and pre-eclampsia. To interpret our findings, the BeWo trophoblast cell line will be used to model the pre-eclamptic damage by exposing syncytialised BeWo to oxidative and inflammatory stress and inducers of apoptosis and necrosis. We will measure changes in soluble molecules released, proportions of STBex and STBmic and the molecules they carry, in response to each treatment to mimic the changes in pre-eclampsia. STBex and STBmic will be phenotyped using fluorescence Nanoparticle Tracking Analysis (fl-NTA - a technique we have pioneered) together with 6 colour flow cytometry. The further development of fl-NTA is a key part of this programme. We will then examine how STBex and STBmic and the miRNAs they carry are taken up by (using imaging flow cytometry, RT-PCR) and affect leucocyte and endothelial functions (cytokine/chemokine production and endothelial cell proliferation/permeability). Based on the danger molecules and miRNAs identified above, we will investigate their effect on syncytialised BeWo and placental explants to determine whether this triggers a vicious cycle of activation which could amplify the underlying problem. Our findings will be used to achieve our final aim, to characterize STBM from peripheral blood of normal pregnant and pre-eclamptic women, in samples from the Oxford Pregnancy Biobank, taken before and during active disease, to determine their use as diagnostic or predictive biomarkers.</gtr:technicalSummary><gtr:potentialImpactText>Who will benefit from this research?

The main beneficiaries from this research apart from other researchers (detailed elsewhere) will be 1) the women who suffer from pre-eclampsia, their unborn children and their families 2) the NHS in terms of cost savings through better prediction and management of pre-eclampsia 3) commercial companies through the exploitation of any biomarkers discovered and the development and sales of new instrumentation for the measurement of microvesicles and exosomes. 

How will they benefit?

1) Patients: The women, children and families will benefit by the development of predictive tests which enable clinicians to identify who is at risk so that antenatal care is focused on them. This will help to avoid unnecessary admissions to hospital which can be very disruptive to family life. The research will also help us develop new treatments which can ameliorate the maternal problems to buy time for the fetus so that it does not need to be delivered too early, with all the inherent risks of prematurity, especially fetal handicap. There is growing evidence that inflammatory stress in pregnancy can cause epigenetic changes in both mother and child which lead to increased risk of cardiovascular disease in later life. Early treatment of these disorders by drugs or lifestyle changes could prevent the development of these problems and lead to significant improvements in quality of life.

2) NHS: These measures would have a major impact on the NHS in terms of cost savings in that they would 1) provide better prediction and management of pre-eclampsia allowing antenatal care to be focused on those who most need it and reduce the amount of unnecessary precautionary admissions of pregnant women to hospital 2) significantly reduce the incidence of pre-term delivery and fetal handicap with its lifelong associated costs 3) reduce the incidence of cardiovascular disease in mother and child in later life and 4) reduce the enormously expensive litigation costs often associated with these cases. 

3) Industry: Commercial companies may benefit through the exploitation of any new biomarkers for pre-eclampsia. The applicants have considerable experience with working with industry. They have established an excellent working relationship with Nanosight Ltd over the last three years for the development of Nanoparticle Tracking Analysis (NTA) technology. This collaboration has put the UK at the forefront of the development of technology to rapidly measure and phenotype microvesicles and exosomes in biological fluids and there is huge potential in terms of instrument sales world wide. The applicants also have links with four companies (Beckman Coulter, Alere, Cyathus and Critical Diagnostics) for the evaluation of biomarkers for pre-eclampsia, one of which has led to a patent application. These companies would be natural partners for future biomarker development.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1866639</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academic Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Standardisation of methodologies for microvesicle and exosome measurement</gtr:description><gtr:id>6585F76F-35E1-4C49-8878-667FBA84E766</gtr:id><gtr:impact>This collaboration has paved the way for the European Metrology Research Programme which is detailed elsewhere.</gtr:impact><gtr:outcomeId>sH683zUuK62-1</gtr:outcomeId><gtr:partnerContribution>Exchange of man made and biological vesicles in order to compare different methodologies for microvesicle and exosome measurement.</gtr:partnerContribution><gtr:piContribution>We have exchanged man made and biological vesicles in order to compare different methodologies for microvesicle and exosome measurement. A manuscript based on this work will be submitted for publication later this year</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academic Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>EURAMET</gtr:description><gtr:id>0497E5B1-FF60-423F-B466-E9AF941878DB</gtr:id><gtr:impact>It is too early in the programme for any measureable outcomes.</gtr:impact><gtr:outcomeId>tLZdCh9NEPZ-1</gtr:outcomeId><gtr:partnerContribution>The research of this JRP is divided into 4 Work Packages (WP). In WP1, methods will be
developed for the standardized collection and handling of human body fluids for isolation of MV, which will be
used as input for the other WP's. Methods, available in metrological institutes, will be explored to measure
the size of single MV, and the size distribution of total MV populations (WP2), chemical composition,
morphology and concentration (WP3). Synthetic and biological reference materials will be tested as
standards for MV measurements (WP4). Selected reference materials will be analysed by all JRP-Partners
and data will be compared between them. The results of this JRP will enable JRP-Partners to perform
traceable calibrations of MV measurements.</gtr:partnerContribution><gtr:piContribution>The European Association of National Metrology Institutes is supporting a Joint Research Programme entitled &amp;quot;Metrological characterisation of micro-vesicles from body fluids as non-invasive diagnostic biomarkers&amp;quot;. The aim of this programme is to develop reliable, comparable and quantitative methods for analysis of microvesicles in biological fluids. Professor Sargent and Dr Gardiner are Stakeholders in this programme and their contribution is to analyse standard vesicle preparations (which are circulated to all members of the programme) using Nanoparticle Tracking Analysis to compare with other technologies used by other groups.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physiology, Anatomy and Genetics</gtr:department><gtr:description>Characterisation of exosomes for use in gene therapy, molecular diagnostics and basic neuroscience research</gtr:description><gtr:id>BAFEACDF-FB33-4DF7-9A60-3D021FC06765</gtr:id><gtr:impact>Publication of the methodology in Nature Protocols (in press).</gtr:impact><gtr:outcomeId>pioCEc4vcx9-1</gtr:outcomeId><gtr:partnerContribution>Provision of unlabelled and green fluorescent protein expressing exosomes for Nanoparticle Tracking Analysis.</gtr:partnerContribution><gtr:piContribution>We have developed standard protocols for Nanoparticle Tracking Analysis of exosomes and microvesicles as well as techniques for the characterisation of exosomes expressing green fluorescent proteins.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aix-Marseille University</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>EURAMET</gtr:description><gtr:id>8F4632A6-D3D8-44B7-B117-6393E24A5439</gtr:id><gtr:impact>It is too early in the programme for any measureable outcomes.</gtr:impact><gtr:outcomeId>tLZdCh9NEPZ-2</gtr:outcomeId><gtr:partnerContribution>The research of this JRP is divided into 4 Work Packages (WP). In WP1, methods will be
developed for the standardized collection and handling of human body fluids for isolation of MV, which will be
used as input for the other WP's. Methods, available in metrological institutes, will be explored to measure
the size of single MV, and the size distribution of total MV populations (WP2), chemical composition,
morphology and concentration (WP3). Synthetic and biological reference materials will be tested as
standards for MV measurements (WP4). Selected reference materials will be analysed by all JRP-Partners
and data will be compared between them. The results of this JRP will enable JRP-Partners to perform
traceable calibrations of MV measurements.</gtr:partnerContribution><gtr:piContribution>The European Association of National Metrology Institutes is supporting a Joint Research Programme entitled &amp;quot;Metrological characterisation of micro-vesicles from body fluids as non-invasive diagnostic biomarkers&amp;quot;. The aim of this programme is to develop reliable, comparable and quantitative methods for analysis of microvesicles in biological fluids. Professor Sargent and Dr Gardiner are Stakeholders in this programme and their contribution is to analyse standard vesicle preparations (which are circulated to all members of the programme) using Nanoparticle Tracking Analysis to compare with other technologies used by other groups.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Twente</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Faculty of Science and Technology</gtr:department><gtr:description>EURAMET</gtr:description><gtr:id>3669CAB6-00C9-4E6A-8D6C-C64EAC4B69F3</gtr:id><gtr:impact>It is too early in the programme for any measureable outcomes.</gtr:impact><gtr:outcomeId>tLZdCh9NEPZ-5</gtr:outcomeId><gtr:partnerContribution>The research of this JRP is divided into 4 Work Packages (WP). In WP1, methods will be
developed for the standardized collection and handling of human body fluids for isolation of MV, which will be
used as input for the other WP's. Methods, available in metrological institutes, will be explored to measure
the size of single MV, and the size distribution of total MV populations (WP2), chemical composition,
morphology and concentration (WP3). Synthetic and biological reference materials will be tested as
standards for MV measurements (WP4). Selected reference materials will be analysed by all JRP-Partners
and data will be compared between them. The results of this JRP will enable JRP-Partners to perform
traceable calibrations of MV measurements.</gtr:partnerContribution><gtr:piContribution>The European Association of National Metrology Institutes is supporting a Joint Research Programme entitled &amp;quot;Metrological characterisation of micro-vesicles from body fluids as non-invasive diagnostic biomarkers&amp;quot;. The aim of this programme is to develop reliable, comparable and quantitative methods for analysis of microvesicles in biological fluids. Professor Sargent and Dr Gardiner are Stakeholders in this programme and their contribution is to analyse standard vesicle preparations (which are circulated to all members of the programme) using Nanoparticle Tracking Analysis to compare with other technologies used by other groups.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Free University of Amsterdam</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Department of Gynaecologic Oncology</gtr:department><gtr:description>EURAMET</gtr:description><gtr:id>23538A02-F24E-491A-B550-FF6CCCB28FF1</gtr:id><gtr:impact>It is too early in the programme for any measureable outcomes.</gtr:impact><gtr:outcomeId>tLZdCh9NEPZ-4</gtr:outcomeId><gtr:partnerContribution>The research of this JRP is divided into 4 Work Packages (WP). In WP1, methods will be
developed for the standardized collection and handling of human body fluids for isolation of MV, which will be
used as input for the other WP's. Methods, available in metrological institutes, will be explored to measure
the size of single MV, and the size distribution of total MV populations (WP2), chemical composition,
morphology and concentration (WP3). Synthetic and biological reference materials will be tested as
standards for MV measurements (WP4). Selected reference materials will be analysed by all JRP-Partners
and data will be compared between them. The results of this JRP will enable JRP-Partners to perform
traceable calibrations of MV measurements.</gtr:partnerContribution><gtr:piContribution>The European Association of National Metrology Institutes is supporting a Joint Research Programme entitled &amp;quot;Metrological characterisation of micro-vesicles from body fluids as non-invasive diagnostic biomarkers&amp;quot;. The aim of this programme is to develop reliable, comparable and quantitative methods for analysis of microvesicles in biological fluids. Professor Sargent and Dr Gardiner are Stakeholders in this programme and their contribution is to analyse standard vesicle preparations (which are circulated to all members of the programme) using Nanoparticle Tracking Analysis to compare with other technologies used by other groups.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Curie Institute Paris (Institut Curie)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Immunity and Cancer INSERM (U932)</gtr:department><gtr:description>EURAMET</gtr:description><gtr:id>41A8122D-37AC-4AAD-B075-179C39FABD1B</gtr:id><gtr:impact>It is too early in the programme for any measureable outcomes.</gtr:impact><gtr:outcomeId>tLZdCh9NEPZ-6</gtr:outcomeId><gtr:partnerContribution>The research of this JRP is divided into 4 Work Packages (WP). In WP1, methods will be
developed for the standardized collection and handling of human body fluids for isolation of MV, which will be
used as input for the other WP's. Methods, available in metrological institutes, will be explored to measure
the size of single MV, and the size distribution of total MV populations (WP2), chemical composition,
morphology and concentration (WP3). Synthetic and biological reference materials will be tested as
standards for MV measurements (WP4). Selected reference materials will be analysed by all JRP-Partners
and data will be compared between them. The results of this JRP will enable JRP-Partners to perform
traceable calibrations of MV measurements.</gtr:partnerContribution><gtr:piContribution>The European Association of National Metrology Institutes is supporting a Joint Research Programme entitled &amp;quot;Metrological characterisation of micro-vesicles from body fluids as non-invasive diagnostic biomarkers&amp;quot;. The aim of this programme is to develop reliable, comparable and quantitative methods for analysis of microvesicles in biological fluids. Professor Sargent and Dr Gardiner are Stakeholders in this programme and their contribution is to analyse standard vesicle preparations (which are circulated to all members of the programme) using Nanoparticle Tracking Analysis to compare with other technologies used by other groups.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>The role of placenta vesicles and free fetal haemoglobin in pre-eclampsia</gtr:description><gtr:id>9D59CD7C-2915-48A0-A58E-EFD630B95B1D</gtr:id><gtr:impact>The first publication is under review by Placenta</gtr:impact><gtr:outcomeId>BHhSEahVyw2-1</gtr:outcomeId><gtr:partnerContribution>Provision of perfusates from placentas treated with fetal haemoglobin</gtr:partnerContribution><gtr:piContribution>Measurement of microvesicles and exosomes in perfusates from placentas treated with fetal haemoglobin</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of North Carolina at Chapel Hill</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>UNC School of Medicine</gtr:department><gtr:description>EURAMET</gtr:description><gtr:id>9E5E8772-7E93-4DA8-9C43-ADE91BE6F09F</gtr:id><gtr:impact>It is too early in the programme for any measureable outcomes.</gtr:impact><gtr:outcomeId>tLZdCh9NEPZ-3</gtr:outcomeId><gtr:partnerContribution>The research of this JRP is divided into 4 Work Packages (WP). In WP1, methods will be
developed for the standardized collection and handling of human body fluids for isolation of MV, which will be
used as input for the other WP's. Methods, available in metrological institutes, will be explored to measure
the size of single MV, and the size distribution of total MV populations (WP2), chemical composition,
morphology and concentration (WP3). Synthetic and biological reference materials will be tested as
standards for MV measurements (WP4). Selected reference materials will be analysed by all JRP-Partners
and data will be compared between them. The results of this JRP will enable JRP-Partners to perform
traceable calibrations of MV measurements.</gtr:partnerContribution><gtr:piContribution>The European Association of National Metrology Institutes is supporting a Joint Research Programme entitled &amp;quot;Metrological characterisation of micro-vesicles from body fluids as non-invasive diagnostic biomarkers&amp;quot;. The aim of this programme is to develop reliable, comparable and quantitative methods for analysis of microvesicles in biological fluids. Professor Sargent and Dr Gardiner are Stakeholders in this programme and their contribution is to analyse standard vesicle preparations (which are circulated to all members of the programme) using Nanoparticle Tracking Analysis to compare with other technologies used by other groups.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>The role of microvesicles and exosomes in the systemic response to brain injury</gtr:description><gtr:id>C22F9F8A-6FDB-4BB3-80A0-52A98ED522A4</gtr:id><gtr:impact>The first publication is in preparation.</gtr:impact><gtr:outcomeId>YmTqjgrEtWz-1</gtr:outcomeId><gtr:partnerContribution>Establishment of the mouse model of brain injury and provision of plasma for Nanoparticle Tracking Analysis of microvesicles and exosomes.</gtr:partnerContribution><gtr:piContribution>We have used Nanoparticle Tracking Analysis to the study the role of microvesicles and exosomes and the pharmacological control of the systemic response to brain injury in a mouse model.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1320</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ERASMUS</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>28972-IC-1-2007-1-NL-ERASMUS-EUCX-1</gtr:fundingRef><gtr:id>EEB5FB53-9326-412F-9D3C-A136DBB9A185</gtr:id><gtr:outcomeId>aFWd6rK8aX4</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Characterisation of Trophoblast Extracellular Vesicles in Gestational Diabetes Mellitus</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Janssen Diagnostics</gtr:fundingOrg><gtr:id>8B0EEDBE-E9EB-4069-B1A0-4BD3983FF4DF</gtr:id><gtr:outcomeId>58b559b6c7b169.31017910</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Roche Diagnostics</gtr:department><gtr:description>Placental Biomarkers for Assessment of Preeclampsia</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>F. Hoffmann-La Roche AG</gtr:fundingOrg><gtr:id>D3958A95-3A96-4889-85DE-1C8351F0C9C8</gtr:id><gtr:outcomeId>58b55b15573732.33618444</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Nanosight Ltd</gtr:companyName><gtr:description>NanoSight visualizes, measures and characterizes virtually all nanoparticles. Particle size, concentration, zeta potential and aggregation can all be analyzed while a fluorescence mode provides speciation of labeled particles. NanoSight provides real time monitoring of the subtle changes in the characteristics of particle populations with all of these analyses uniquely confirmed by visual validation.

http://www.nanosight.com/</gtr:description><gtr:id>61FD6932-0CB5-44B6-BB45-2D7FDCA3DBF4</gtr:id><gtr:impact>In 2011 NanoSight won Technology World's 2011 Business Innovation Award and was recognised by Deloitte as the UK's Fastest Growing Biotech Company . 
In 2012 NanoSight wins Queen's Award for Enterprise for International Trade, having achieved their 450th instrument sale with more than 400 third party papers citing NanoSight technology. Much of this success has come directly from our collaboration with them in which we use their technology to measure microvesicles and exosomes in biological fluids.
 
2011
 NanoSight wins Technology World's 2011 Business Innovation Award
 
 NanoSight Recognised by Deloitte as the UK's Fastest Growing Biotech Company in their 2011 Technology Fast 50 Rankings

2013 On the basis of the above success, Nanosight Ltd was sold to Malvern Instruments for &amp;pound;15 million.</gtr:impact><gtr:outcomeId>PcDzzZH1Pzk</gtr:outcomeId><gtr:url>http://www.nanosight.com/</gtr:url></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>B9067DC0-4613-4D64-AEA0-2BBE6F3D15BB</gtr:id><gtr:title>Platelets</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb40bb60743948fdebfd91443904734b"><gtr:id>fb40bb60743948fdebfd91443904734b</gtr:id><gtr:otherNames>Nieuwland Rink, Gardiner Christopher, Sturk August</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>0123878373</gtr:isbn><gtr:outcomeId>NJcmoZWzbDX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F0A29A5-A10D-4649-9027-9BC89887E18E</gtr:id><gtr:title>International Society for Extracellular Vesicles: Second Annual Meeting, 17-20 April 2013, Boston, MA (ISEV 2013).</gtr:title><gtr:parentPublicationTitle>Journal of extracellular vesicles</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0bba5d6f3bb821884646b2857d24e8f"><gtr:id>d0bba5d6f3bb821884646b2857d24e8f</gtr:id><gtr:otherNames>Aikawa E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2001-3078</gtr:issn><gtr:outcomeId>564b268d238c65.12770055</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB09FB82-F3DE-4DA3-B84E-883215D9DF7C</gtr:id><gtr:title>Syncytiotrophoblast vesicles show altered micro-RNA and haemoglobin content after ex-vivo perfusion of placentas with haemoglobin to mimic preeclampsia.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fc380e241376db018d5e5fe13d85782"><gtr:id>7fc380e241376db018d5e5fe13d85782</gtr:id><gtr:otherNames>Cronqvist T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545b37869a8de6.76031587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>404A27BE-5A8C-429D-9BEA-DBFBD26358CC</gtr:id><gtr:title>Differential activation of Fyn kinase distinguishes saturated and unsaturated fats in mouse macrophages.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6749716d9f20f540c456abf327805a7"><gtr:id>d6749716d9f20f540c456abf327805a7</gtr:id><gtr:otherNames>Tarabra E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5a9e508dce1e31.37970598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C33BF2E-4D60-46DB-8B1F-266B1BE0A14C</gtr:id><gtr:title>Syncytiotrophoblast extracellular vesicles impair rat uterine vascular function via the lectin-like oxidized LDL receptor-1.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7465f298814e0b37a2d49bb422ffd5ca"><gtr:id>7465f298814e0b37a2d49bb422ffd5ca</gtr:id><gtr:otherNames>Spaans F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a2fd2a86f9435.33626606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A36E583-DBF8-4AFE-8E5E-E89C82578A08</gtr:id><gtr:title>Endoplasmic reticulum stress stimulates the release of extracellular vesicles carrying danger-associated molecular pattern (DAMP) molecules.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75e61a3d31b1473e87a3bde2ab792ab9"><gtr:id>75e61a3d31b1473e87a3bde2ab792ab9</gtr:id><gtr:otherNames>Collett GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5a9e508cc39e93.30719404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FACAFA9-1A7D-4C83-B1C8-D30F6C8C9649</gtr:id><gtr:title>Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d992a2a4f63bf79792f094bfaa32a4cd"><gtr:id>d992a2a4f63bf79792f094bfaa32a4cd</gtr:id><gtr:otherNames>Agrawal S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5a9e508d005ac2.57796424</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BF69231-FC4B-48BF-98D0-164A4E87BA49</gtr:id><gtr:title>Microvesicles and Exosomes in Health and Disease</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfdbc33990ed1096fbb0278040187ce8"><gtr:id>bfdbc33990ed1096fbb0278040187ce8</gtr:id><gtr:otherNames>Sargent IL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>?9789814411981</gtr:isbn><gtr:outcomeId>f471pmR7BnH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9C03643-8B96-48A2-8DC9-A4DBBA5EE127</gtr:id><gtr:title>Obituary.</gtr:title><gtr:parentPublicationTitle>Journal of extracellular vesicles</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6b46e19ab6f707e973bbe995824b073"><gtr:id>f6b46e19ab6f707e973bbe995824b073</gtr:id><gtr:otherNames>Hochberg F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2001-3078</gtr:issn><gtr:outcomeId>564b268d4dbe58.25619152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8108B827-C997-418E-86B3-28857CE4FEEC</gtr:id><gtr:title>Measurement of sST2 is comparable to PlGF in the diagnosis of early-onset pre-eclampsia.</gtr:title><gtr:parentPublicationTitle>Pregnancy hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/200b663e61c22e47e47cbdc7fbe8bb80"><gtr:id>200b663e61c22e47e47cbdc7fbe8bb80</gtr:id><gtr:otherNames>Southcombe JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2210-7789</gtr:issn><gtr:outcomeId>chWQ1bSa3RU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C034BF08-D67A-4041-A942-2F5DC3C42057</gtr:id><gtr:title>IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia?</gtr:title><gtr:parentPublicationTitle>Placenta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d3fe95972c429a22e7543711c1e7390"><gtr:id>8d3fe95972c429a22e7543711c1e7390</gtr:id><gtr:otherNames>Redman CW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0143-4004</gtr:issn><gtr:outcomeId>545b3731037c77.43975256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9216177-D94B-4D37-8A5F-AD333AE037D0</gtr:id><gtr:title>Secretions from placenta, after hypoxia/reoxygenation, can damage developing neurones of brain under experimental conditions.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09f18d702c2f12327d244aa5954da2e1"><gtr:id>09f18d702c2f12327d244aa5954da2e1</gtr:id><gtr:otherNames>Curtis DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>545b37f8743458.97241634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACCDC3DB-D7B3-43DC-AB5C-E8EFBA8C68BD</gtr:id><gtr:title>IFPA Meeting 2013 Workshop Report III: maternal placental immunological interactions, novel determinants of trophoblast cell fate, dual ex vivo perfusion of the human placenta.</gtr:title><gtr:parentPublicationTitle>Placenta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2380fa58f4de9c64a91447b2d9c2cd40"><gtr:id>2380fa58f4de9c64a91447b2d9c2cd40</gtr:id><gtr:otherNames>Abumaree MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0143-4004</gtr:issn><gtr:outcomeId>545b5e92ae1f40.54407550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52126FBD-1445-4E0E-96B5-18B49567B0EF</gtr:id><gtr:title>Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32238a7805ba069b29dfb9f96b1df898"><gtr:id>32238a7805ba069b29dfb9f96b1df898</gtr:id><gtr:otherNames>van der Pol E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>545b38cc7801e7.02067161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>985668CC-72B8-40A3-8F69-E561D10B72B9</gtr:id><gtr:title>Syncytiotrophoblast Extracellular Vesicles from Pre-Eclampsia Placentas Differentially Affect Platelet Function.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd79d9229faed077593970c5404153db"><gtr:id>dd79d9229faed077593970c5404153db</gtr:id><gtr:otherNames>Tannetta DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>564b225821ce25.71276200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>835F8837-B47C-4BED-B9B1-E347C993FB14</gtr:id><gtr:title>Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis.</gtr:title><gtr:parentPublicationTitle>Journal of extracellular vesicles</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31e8d69b0f956e43ce27b1b3fa27aa81"><gtr:id>31e8d69b0f956e43ce27b1b3fa27aa81</gtr:id><gtr:otherNames>Gardiner C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2001-3078</gtr:issn><gtr:outcomeId>pm_13671_21_24009893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2A991AE-2365-430D-8DBE-FE78F1B43E4A</gtr:id><gtr:title>Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a49392451d14de11f6d8a28bd0e7ceba"><gtr:id>a49392451d14de11f6d8a28bd0e7ceba</gtr:id><gtr:otherNames>Roberts TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>pm_13671_21_23945935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1290787-70AA-41B1-B782-89B1B82F1D01</gtr:id><gtr:title>Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57102d51b4ad8239800963ce233beb87"><gtr:id>57102d51b4ad8239800963ce233beb87</gtr:id><gtr:otherNames>Ukah UV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5a9e508d277930.00433024</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAA92583-EADD-41FA-9A06-4806CB41A020</gtr:id><gtr:title>Invisible vesicles swarm within the iceberg.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a319434a04156bcbe84d7902d4a68b45"><gtr:id>a319434a04156bcbe84d7902d4a68b45</gtr:id><gtr:otherNames>Harrison P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>c6SEoarFS3n</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CE166E6-F718-4F51-8548-505E44C82CEB</gtr:id><gtr:title>Measurement of refractive index by nanoparticle tracking analysis reveals heterogeneity in extracellular vesicles.</gtr:title><gtr:parentPublicationTitle>Journal of extracellular vesicles</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31e8d69b0f956e43ce27b1b3fa27aa81"><gtr:id>31e8d69b0f956e43ce27b1b3fa27aa81</gtr:id><gtr:otherNames>Gardiner C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2001-3078</gtr:issn><gtr:outcomeId>564b22579cbb26.98970008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34734401-DBF2-4DB1-8F2C-B07CD22E9D5E</gtr:id><gtr:title>OS045. Multi-dimensional protein identification technology analysis of syncytiotrophoblast vesicles released from perfused preeclampsia placentas.</gtr:title><gtr:parentPublicationTitle>Pregnancy hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbe97d44002a7caa57902a3b8a2204da"><gtr:id>bbe97d44002a7caa57902a3b8a2204da</gtr:id><gtr:otherNames>Tannetta D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2210-7789</gtr:issn><gtr:outcomeId>564b2257610750.27813128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2576763D-6E54-4472-96E3-19D57FF41E7E</gtr:id><gtr:title>Syncytiotrophoblast extracellular vesicles - Circulating biopsies reflecting placental health.</gtr:title><gtr:parentPublicationTitle>Placenta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbe97d44002a7caa57902a3b8a2204da"><gtr:id>bbe97d44002a7caa57902a3b8a2204da</gtr:id><gtr:otherNames>Tannetta D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0143-4004</gtr:issn><gtr:outcomeId>58b558ed1c2396.53332539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CA9D627-AA20-42F2-B281-793D76B3CB29</gtr:id><gtr:title>Extracellular vesicles and reproduction-promotion of successful pregnancy.</gtr:title><gtr:parentPublicationTitle>Cellular &amp; molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbe97d44002a7caa57902a3b8a2204da"><gtr:id>bbe97d44002a7caa57902a3b8a2204da</gtr:id><gtr:otherNames>Tannetta D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1672-7681</gtr:issn><gtr:outcomeId>545b5e575cc251.90637589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>062E4F38-7E9E-4C4B-AAE2-6CD5BB393C78</gtr:id><gtr:title>Review: Does size matter? Placental debris and the pathophysiology of pre-eclampsia.</gtr:title><gtr:parentPublicationTitle>Placenta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d3fe95972c429a22e7543711c1e7390"><gtr:id>8d3fe95972c429a22e7543711c1e7390</gtr:id><gtr:otherNames>Redman CW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0143-4004</gtr:issn><gtr:outcomeId>pm_13671_21_22217911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B8937C0-CA6D-4326-808A-40A61E9FFEB2</gtr:id><gtr:title>Extracellular Vesicles in Health and Disease</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31e8d69b0f956e43ce27b1b3fa27aa81"><gtr:id>31e8d69b0f956e43ce27b1b3fa27aa81</gtr:id><gtr:otherNames>Gardiner C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-981-4411-98-1</gtr:isbn><gtr:outcomeId>Yb4q3Yg3U2A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E326FC01-AAE8-4FBE-911D-BDFC18A941F3</gtr:id><gtr:title>Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/508dc2ab104f9d15b4624f4ffb50d35a"><gtr:id>508dc2ab104f9d15b4624f4ffb50d35a</gtr:id><gtr:otherNames>Davis EF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>pm_13671_21_22614768</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>045D8712-B0E7-4A83-86B2-4D47A3289143</gtr:id><gtr:title>Identification of distinct circulating exosomes in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Annals of clinical and translational neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6de5ee73dccccec3d9bb9e85c3b55fc4"><gtr:id>6de5ee73dccccec3d9bb9e85c3b55fc4</gtr:id><gtr:otherNames>Tomlinson PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2328-9503</gtr:issn><gtr:outcomeId>564b2590b344b0.78468635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BF87D2B-D131-4901-92DE-8A61FB49CFEA</gtr:id><gtr:title>EVpedia: a community web portal for extracellular vesicles research.</gtr:title><gtr:parentPublicationTitle>Bioinformatics (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7180b62b3059eaa31145b838f5630fc4"><gtr:id>7180b62b3059eaa31145b838f5630fc4</gtr:id><gtr:otherNames>Kim DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1367-4803</gtr:issn><gtr:outcomeId>564b268d75ca98.78862282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32E613CC-EB2D-4EF3-9A7B-BA5401F9C4E7</gtr:id><gtr:title>RhoE is regulated by cyclic AMP and promotes fusion of human BeWo choriocarcinoma cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75e61a3d31b1473e87a3bde2ab792ab9"><gtr:id>75e61a3d31b1473e87a3bde2ab792ab9</gtr:id><gtr:otherNames>Collett GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13671_21_22272352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46812B0D-74B6-4B4A-A444-81F462292431</gtr:id><gtr:title>Placental disease and the maternal syndrome of preeclampsia: missing links?</gtr:title><gtr:parentPublicationTitle>Current hypertension reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbe97d44002a7caa57902a3b8a2204da"><gtr:id>bbe97d44002a7caa57902a3b8a2204da</gtr:id><gtr:otherNames>Tannetta D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1522-6417</gtr:issn><gtr:outcomeId>EQ84wQ3LdTY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1319264D-1FA6-4383-8A1D-5D7B888677C6</gtr:id><gtr:title>Exosome-mediated delivery of siRNA in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f17fb92aa86d9a83bfb913a850fe197"><gtr:id>7f17fb92aa86d9a83bfb913a850fe197</gtr:id><gtr:otherNames>El-Andaloussi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn><gtr:outcomeId>QNRgW2g29Xn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4885BD37-FA91-484D-A087-2B4B64CA9B6E</gtr:id><gtr:title>Interleukin-1 family cytokines and their regulatory proteins in normal pregnancy and pre-eclampsia.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/200b663e61c22e47e47cbdc7fbe8bb80"><gtr:id>200b663e61c22e47e47cbdc7fbe8bb80</gtr:id><gtr:otherNames>Southcombe JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>54e1f58378b194.66885647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>216B2D9E-CBB1-42D2-A0F3-F958C6DD5EB9</gtr:id><gtr:title>Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation?</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/337e31491360ca04a46c1aa407d73aec"><gtr:id>337e31491360ca04a46c1aa407d73aec</gtr:id><gtr:otherNames>Davila M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>545b36d7d3fb34.37178768</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AAAA4C2-8F24-4D38-A373-E154D3BB1B1E</gtr:id><gtr:title>Update of syncytiotrophoblast derived extracellular vesicles in normal pregnancy and preeclampsia.</gtr:title><gtr:parentPublicationTitle>Journal of reproductive immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbe97d44002a7caa57902a3b8a2204da"><gtr:id>bbe97d44002a7caa57902a3b8a2204da</gtr:id><gtr:otherNames>Tannetta D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0165-0378</gtr:issn><gtr:outcomeId>58b558ed706516.19274899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F02E1E0C-A37D-49AB-BF21-CCC374E4E863</gtr:id><gtr:title>Angiogenic factors: potential to change clinical practice in pre-eclampsia?</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1bad603b34ac0561a89a85dcd98d700"><gtr:id>f1bad603b34ac0561a89a85dcd98d700</gtr:id><gtr:otherNames>Cerdeira AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn><gtr:outcomeId>5a9e508d4ec887.59634951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6C83F5A-FF3A-4B2D-A68A-874BD15EAEE1</gtr:id><gtr:title>A New Enzyme-linked Sorbent Assay (ELSA) to Quantify Syncytiotrophoblast Extracellular Vesicles in Biological Fluids.</gtr:title><gtr:parentPublicationTitle>American journal of reproductive immunology (New York, N.Y. : 1989)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecc08e40dee87e7ade0747e8a082d3e8"><gtr:id>ecc08e40dee87e7ade0747e8a082d3e8</gtr:id><gtr:otherNames>G?hner C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1046-7408</gtr:issn><gtr:outcomeId>564b2257c5a090.49193518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9E66F24-551F-4247-952F-99DC3C63811B</gtr:id><gtr:title>Isolation of syncytiotrophoblast microvesicles and exosomes and their characterisation by multicolour flow cytometry and fluorescence Nanoparticle Tracking Analysis.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd5732b831b1b79d5365097f0a6f08f2"><gtr:id>fd5732b831b1b79d5365097f0a6f08f2</gtr:id><gtr:otherNames>Dragovic RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn><gtr:outcomeId>564b2257f0c4a9.64353253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4E3DF14-C7EA-4D40-9054-32DB32D91F26</gtr:id><gtr:title>Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles.</gtr:title><gtr:parentPublicationTitle>Journal of extracellular vesicles</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd792e4024bcd7a428d97154ff7fa628"><gtr:id>dd792e4024bcd7a428d97154ff7fa628</gtr:id><gtr:otherNames>L?tvall J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2001-3078</gtr:issn><gtr:outcomeId>564b268dacca41.15897261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF3BFB20-0DB7-45DA-B715-EF1F7D8222C1</gtr:id><gtr:title>Multicolor flow cytometry and nanoparticle tracking analysis of extracellular vesicles in the plasma of normal pregnant and pre-eclamptic women.</gtr:title><gtr:parentPublicationTitle>Biology of reproduction</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd5732b831b1b79d5365097f0a6f08f2"><gtr:id>fd5732b831b1b79d5365097f0a6f08f2</gtr:id><gtr:otherNames>Dragovic RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3363</gtr:issn><gtr:outcomeId>NpcXNNVihxe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>933FFE8D-9E85-43A3-A1B9-94ED642401B0</gtr:id><gtr:title>Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia.</gtr:title><gtr:parentPublicationTitle>Journal of neuroinflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5027e51c161415b715ac775758873332"><gtr:id>5027e51c161415b715ac775758873332</gtr:id><gtr:otherNames>Clausen BH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-2094</gtr:issn><gtr:outcomeId>564b2875d9f9a7.54777878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F80C66EC-37A3-43B8-B946-A8F087F2A840</gtr:id><gtr:title>Complement component C1q as potential diagnostic but not predictive marker of preeclampsia.</gtr:title><gtr:parentPublicationTitle>American journal of reproductive immunology (New York, N.Y. : 1989)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af3b8ea6dc14e4ac9cf012cad4453d4b"><gtr:id>af3b8ea6dc14e4ac9cf012cad4453d4b</gtr:id><gtr:otherNames>Agostinis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1046-7408</gtr:issn><gtr:outcomeId>58b558ed4443b8.75105291</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88EAD457-4525-4793-A47E-6E1E426D69C2</gtr:id><gtr:title>Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: expression of Flt-1 and endoglin.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd79d9229faed077593970c5404153db"><gtr:id>dd79d9229faed077593970c5404153db</gtr:id><gtr:otherNames>Tannetta DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13671_21_23437230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C56C553-A666-4B3F-A8E4-705BEEA42A87</gtr:id><gtr:title>Optimising sample collection for placental research.</gtr:title><gtr:parentPublicationTitle>Placenta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c8853772b294cb036b725979742c77b"><gtr:id>8c8853772b294cb036b725979742c77b</gtr:id><gtr:otherNames>Burton GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0143-4004</gtr:issn><gtr:outcomeId>545b5ed42699f0.67019236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99D3F061-A2A8-469D-AA7A-5A2DBEA9FE17</gtr:id><gtr:title>Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 Educational Day.</gtr:title><gtr:parentPublicationTitle>Journal of extracellular vesicles</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31e8d69b0f956e43ce27b1b3fa27aa81"><gtr:id>31e8d69b0f956e43ce27b1b3fa27aa81</gtr:id><gtr:otherNames>Gardiner C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2001-3078</gtr:issn><gtr:outcomeId>564b268dd12fe9.98780041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD1DE646-1C37-48CF-80AF-2C0DA7304FEF</gtr:id><gtr:title>Incorporation of ophiobolin a into novel chemoembolization particles for cancer cell treatment.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41a65e05e79b25b5a7db3fa8c4a9768c"><gtr:id>41a65e05e79b25b5a7db3fa8c4a9768c</gtr:id><gtr:otherNames>Morrison R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0724-8741</gtr:issn><gtr:outcomeId>545b60104b2708.22999383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59BC088B-493C-4B07-ADEE-96293D496785</gtr:id><gtr:title>Investigation of the actin scavenging system in pre-eclampsia.</gtr:title><gtr:parentPublicationTitle>European journal of obstetrics, gynecology, and reproductive biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd79d9229faed077593970c5404153db"><gtr:id>dd79d9229faed077593970c5404153db</gtr:id><gtr:otherNames>Tannetta DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0301-2115</gtr:issn><gtr:outcomeId>CfWQp4yXmEu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A776255D-7CF3-4784-8E4B-4A2787B30075</gtr:id><gtr:title>Placental Vesicles Carry Active Endothelial Nitric Oxide Synthase and Their Activity is Reduced in Preeclampsia.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a3af64cdace7ef16b7583d754767cba"><gtr:id>5a3af64cdace7ef16b7583d754767cba</gtr:id><gtr:otherNames>Motta-Mejia C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>5a31d8f77c91a0.33842430</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J003360/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>